![[Caixin Global] Brand-name drugs feel the squeeze in China’s generic-heavy market episode artwork](https://content.production.cdn.art19.com/images/0a/81/38/0d/0a81380d-b0cc-48e8-80ad-de4537a689a4/3d9269224852b86752e6fa9e25c729060d60317fc8dddefadfd6128f2e91005fd3630f1fb5699a93ca6f27ed2f66151495dda26715a808869635680549b1bdf6.jpeg)
EPISODE · Jun 27, 2023 · 12 MIN
[Caixin Global] Brand-name drugs feel the squeeze in China’s generic-heavy market
from China Stories
Multinational pharmaceutical firms are changing strategies and selling business lines, as a government bulk-buying program favors cheaper, local products.Click here to read the article by Tang Hanyu and Kelly Wang.Narrated by Elyse Ribbons.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
Embed this episode
What this episode covers
Multinational pharmaceutical firms are changing strategies and selling business lines, as a government bulk-buying program favors cheaper, local products.
NOW PLAYING
[Caixin Global] Brand-name drugs feel the squeeze in China’s generic-heavy market
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.